|

DOMVANALIMAB + ZIMBERELIMAB + FOLFOX-4 Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Hospices Civils de Lyon1

Indications

  • Gestational Trophoblastic Tumor1
  • Anaplastic Thyroid Carcinomas1
  • Peritoneal Mesothelioma1
  • Carcinoid Tumor1
  • Gastroenteropancreatic Neuroendocrine Tumor1

Other1 trial

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.